Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Indsamling af blodprøver til nye diagnostiske enheder 2 (NOVEL-2)

12. november 2026 opdateret af: LumiraDx UK Limited

Indsamling af venøse og kapillære blodprøver til forskning, optimering og kalibrering af nye diagnostiske enheder 2

To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.

Studieoversigt

Detaljeret beskrivelse

This is a comparative research study to research, optimise and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that will radically enhance clinicians and patients ability to monitor chronic health conditions which improve outcomes at the point of care and that are comparable to gold standard reference methods. The LumiraDx POC Platform consists of an in vitro diagnostic instrument, used with single use test strips for different disease biomarkers. This next generation point of care device is intended to allow multiple tests to be performed on the same platform for blood, plasma, serum, swab, and urine samples.

Research activities will be completed on blood samples collected from a maximum of 20,000 patients to assess the performance of the new biomarkers undergoing research. Patients will include those presenting at a medical unit (including but not limited to A&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.

Each patient must give appropriate written informed consent and satisfy all the inclusion/exclusion criteria prior to any study procedures. Patient participation in this study will take a maximum of 45 minutes of the patient's time. Patients presenting for a subsequent clinic visit or admission may be approached to participate in the study again, a maximum of 24mL of venous whole blood and up to 6 capillary fingersticks (obtained with a high flow lancet) may be collected from each patient within a three month period. Where possible, study samples should be taken at the same time as any standard of care blood draws or from patients with a cannula in-situ, a separate study venipuncture is not a requirement for this protocol. Study samples will be used for research, evaluation, optimisation and development activities into new biomarkers on the LumiraDx Platform in comparison with the gold standard reference method for the disease area to ensure comparable performance. Samples may also be used for troubleshooting and calibrating LumiraDx assays developed.

Sample collection will be separated into 2 phases depending upon the research needs. Patients can participate in both phases:

Phase 1: Only venous blood samples will be drawn by the HCP. These samples will be tested on the LumiraDx System and/or device(s) under development and also tested on the appropriate reference method for comparison. This testing may occur at the clinical site and/or at LumiraDx UK Ltd.

Phase 2: Venous blood samples and capillary fingerstick samples will be collected by the HCP. These samples may be tested on the LumiraDx Platform and also tested on the appropriate reference method for comparison. The fingerstick samples will be tested on the LumiraDx device. The processing of samples may occur at the clinical site and/or at LumiraDX UK Ltd.

The samples will be identified by patient identification number, anonymising the patient's identifiable information. These blood samples will be sent to LumiraDx UK Ltd for storage and future testing. No genetic testing will be carried out on samples. Samples may also be used to research, optimise, develop, modify and calibrate products and platforms for measuring biomarkers including, but not limited to, Troponin, NT-pro BNP, BNP, CK-MB, D-Dimer, NGAL, Cystatin C, Myoglobin, Galectin-3, CRP, AST, ALT, Lipids, Coagulation, Prolactin, and Beta-hCG.

Patients who reattend or are admitted to the medical unit (including but not limited to A&E departments, hospital wards or out-patient clinics) may be asked for further sampling. A total of 24mL and 6 capillary fingersticks (obtained using high flow lancets) will not be exceeded over the three month period from consent, patients may opt out of further contact. Any patient reattending three months post consent will be treated as a new patient.

Data will be recorded on the Case Report Forms. The patient demographics data collected may include: age; sex; ethnicity, pregnancy status, NYHA classification, current medications at time of blood collection including their indications, significant medical history, relevant local blood test results, reason(s) for presenting, and confirmed diagnosis.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

16063

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Scotland
      • Airdrie, Scotland, Det Forenede Kongerige, ML6 0JS
        • University Hospital Monklands
      • Edinburgh, Scotland, Det Forenede Kongerige, EH16 4SA
        • Royal Infirmary of Edinburgh
      • Edinburgh, Scotland, Det Forenede Kongerige, EH54 6PP
        • St John's Hospital
      • Glasgow, Scotland, Det Forenede Kongerige, G51 4TF
        • Queen Elizabeth University Hospital
      • Glasgow, Scotland, Det Forenede Kongerige, G4 0SF
        • Glasgow Royal Infirmary
      • Glasgow, Scotland, Det Forenede Kongerige, G81 4DY
        • Golden Jubilee National Hospital
      • Paisley, Scotland, Det Forenede Kongerige, PA2 9PN
        • Royal Alexandra Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients will include those presenting at a medical unit (including but not limited to A&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.

Beskrivelse

Inclusion Criteria

  • Subject 18 years of age.

  • Willing and able to provide written informed consent and comply with study procedures.

  • Patients attending a definitive care team with research capabilities which has been enroled in this collection study.

  • Patients who can read and understand written English.

  • The subject must present as one of the following cohorts:

    1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.
    2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.
    3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.
    4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.
    5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.

Exclusion Criteria

  • Subject <18 years of age.
  • Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.
  • Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Blood Draw

Venous blood draw up to 24mL and/or 6 capillary fingersticks

Interventions:

Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick

Venepuncture to draw up to 24mL of venous blood.

Capillary blood draw

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measurement of blood samples from patients with infection, cardiovascular disease, embolism or renal disease in a reference method and in a novel LumiraDx method.
Tidsramme: Up to 5 years

Measurement of blood samples in a reference method and in a novel LumiraDx method to assess accuracy of the LumiraDx method in patients with infection, cardiovascular disease, embolism or renal disease. Accuracy will be assessed by regression analysis against a reference method.

Up to 5 years
Multiple measurements of blood samples from patients with infection, cardiovascular disease, embolism or renal disease in a novel LumiraDx method.
Tidsramme: Up to 5 years

Multiple measurements of blood samples in a novel LumiraDx method to assess precision of the method in patients with infection, cardiovascular disease, embolism or renal disease. Precision will be assessed by coefficient of variation (%CV) estimates.

Up to 5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Roy Gardner, NHS National Waiting Times Centre Board
  • Ledende efterforsker: Alasdair Gray, NHS Lothian
  • Ledende efterforsker: Fiona Hunter, NHS Lanarkshire
  • Ledende efterforsker: Allan Cameron, NHS Greater Glasgow and Clyde
  • Ledende efterforsker: David Lowe, NHS Greater Glasgow and Clyde
  • Ledende efterforsker: Santosh Bongale, NHS Greater Glasgow and Clyde

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. juli 2022

Primær færdiggørelse (Faktiske)

17. september 2026

Studieafslutning (Faktiske)

17. september 2026

Datoer for studieregistrering

Først indsendt

21. september 2022

Først indsendt, der opfyldte QC-kriterier

3. oktober 2022

Først opslået (Faktiske)

6. oktober 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner